Table 1.
Baseline characteristics of randomized subjects
| Overall (n = 24) | Tofo/Ipra (n = 12) | Ipra/Tofo (n = 12) | p-value* | |
|---|---|---|---|---|
| Age (years) | 63.4 ± 11.4 | 64.2 ± 7.6 | 62.7 ± 14.7 | 0.756 |
| Duration of diabetes (years) | 10.1 ± 7.4 | 12.0 ± 9.6 | 8.3 ± 3.8 | 0.220 |
| Sex, male, n (%) | 14 (58.3) | 6 (50.0) | 8 (66.7) | 0.679 |
| BMI (kg/m2) | 26.6 ± 6.2 | 24.9 ± 4.9 | 28.2 ± 7.0 | 0.190 |
| HbA1c (%) | 8.3 ± 1.2 | 8.3 ± 1.3 | 8.3 ± 1.2 | 0.961 |
| S-CPR (ng/ml) | 2.4 ± 1.7 | 2.3 ± 1.7 | 2.5 ± 1.7 | 0.749 |
| eGFR (ml/min/1.73 m2) | 70.1 ± 21.5 | 74.0 ± 21.6 | 66.2 ± 21.5 | 0.389 |
| S-albumin (g/dl) | 4.0 ± 0.5 | 4.0 ± 0.4 | 4.1 ± 0.6 | 0.468 |
| Insulin glargine U300 (U/day) | 13.6 ± 9.2 | 14.8 ± 11.4 | 12.3 ± 6.7 | 0.520 |
| Antihyperglycemic drugs other than SGLT2 inhibitor | ||||
| DPP4 inhibitor, n | 14 | 8 | 6 | 0.679 |
| Metformin, n | 13 | 8 | 5 | 0.413 |
| Sulfonylurea, n | 2 | 2 | 0 | 0.478 |
| Glinide, n | 4 | 1 | 3 | 0.590 |
| α-GI, n | 2 | 1 | 1 | 1.000 |
| GLP-1RA, n | 2 | 1 | 1 | 1.000 |
Data are presented as mean ± SD
Tofo tofogliflozin, Ipra ipragliflozin, Tofo/Ipra switching to ipragliflozin after prior administration of tofogliflozin, Ipra/Tofo switching to tofogliflozin after prior administration of ipragliflozin, BMI body mass index, HbA1c glycated hemoglobin, S-CPR serum C-peptide immunoreactivity, eGFR estimated glomerular filtration rate, S-albumin serum albumin, SGLT2 sodium-glucose cotransporter 2, DPP4 dipeptidyl peptidase-4, α-GI alpha-glucosidase inhibitor, GLP-1RA glucagon-like peptide-1 receptor agonists
*Student’s t-test or χ2 test used to compare data between the two groups. Insulin glargine U300 and antidiabetic drug dosages were not changed throughout the study period